No abstract available
Keywords:
Ozempic; Qsymia; Saxenda; adverse effects; dosage; efficacy; liraglutide; phentermine; safety; semaglutide; topiramate; type 2 diabetes; weight loss.
MeSH terms
-
Anti-Obesity Agents / adverse effects
-
Anti-Obesity Agents / therapeutic use*
-
Glucagon-Like Peptide-1 Receptor Agonists
-
Glucagon-Like Peptides / adverse effects
-
Glucagon-Like Peptides / therapeutic use*
-
Humans
-
Incretins / adverse effects
-
Incretins / therapeutic use*
-
Obesity / diagnosis
-
Obesity / drug therapy*
-
Obesity / physiopathology
-
Treatment Outcome
-
Weight Loss / drug effects*
Substances
-
Anti-Obesity Agents
-
GLP1R protein, human
-
Incretins
-
semaglutide
-
Glucagon-Like Peptides
-
Glucagon-Like Peptide-1 Receptor Agonists